Jiangsu Hengrui Medicine Enters into Agreement with The University of Texas MD Anderson Cancer Center to Advance Immunotherapy and Precision Medicine for Cancer Treatment

LIANYUNGANG, China, May 3, 2016 /PRNewswire/ -- Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) and The University of Texas MD Anderson Cancer Center (MD Anderson) have entered into a research agreement to advance cancer treatment. The 3-year agreement for translational research brings together the scientific and clinical capabilities of MD Anderson and Jiangsu Hengrui Medicine to develop rational combination therapies and personalized medicines as well as to identify new treatment opportunities, especially in the field of immuno-oncology.

"Hengrui plays a leading role in cancer drug discovery and development in China. We are very pleased with our collaboration with MD Anderson and look forward to working closely with MD Anderson to jointly improve the care of cancer patients. The collaboration will also further strengthen Hengrui's leading position in oncology drug development in China, especially in the field of personalized medicine and immuno-oncology," said Dr. Guoqing Cao, Vice President of Jiangsu Hengrui Medicine.

About Jiangsu Hengrui Medicine Co., Ltd

Jiangsu Hengrui Medicine Co., Ltd, established in 1970, is a fully integrated pharmaceutical company in China, with annual net sales of over $1.2 billion (USD). Hengrui's products and innovative R&D span multiple therapeutic areas, including oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and inflammation. Visit http://www.hrs.com.cn for further information.

SOURCE Jiangsu Hengrui Medicine Co., Ltd

Related Links

http://www.hrs.com.cn